Clinical Trial Update: Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing whether atorvastatin can prevent contrast-induced nephropathy in patients undergoing coronary angiography.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy

Drugs mentioned

• atorvastatin (atorvastatin)

Snippet

Sponsor: Isfahan University of Medical Sciences | Conditions: Contrast Induced Nephropathy | Phase 3 | Status: UNKNOWN